Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cong Wu

Showing results (431-440 of 434) with videos related to

Pageof 44
Sort By:
You have reached the last page of results.This site can display upto 434 results.
Frontiers in Immunology|July 11, 2022
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 TrialShengli Xia, Kai Duan, Yuntao Zhang, et al.
Eclinicalmedicine|July 12, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trialWanshen Guo, Kai Duan, Yuntao Zhang, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Virologica Sinica|August 4, 2022
Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infantsZhiwei Wu, Qingliang Li, Yan Liu, et al.
Pageof 44

Showing results (431-440 of 434) with videos related to

Sort By:
Pageof 44
You have reached the last page of results.This site can display upto 434 results.
Frontiers in Immunology|July 11, 2022
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 TrialShengli Xia, Kai Duan, Yuntao Zhang, et al.
Eclinicalmedicine|July 12, 2021
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trialWanshen Guo, Kai Duan, Yuntao Zhang, et al.
Chemical Science|April 13, 2022
A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptidesNeelie Zacharias, Vladimir N Podust, Kimberly K Kajihara, et al.
Virologica Sinica|August 4, 2022
Efficacy, safety and immunogenicity of hexavalent rotavirus vaccine in Chinese infantsZhiwei Wu, Qingliang Li, Yan Liu, et al.
Pageof 44